Research

Researchers have identified two FDA-approved drugs that may be effective against the Ebola virus. This could shorten the time for developing new treatments.

HEALTHLINE NEWS  by  Shawn Radcliffe                                                         June 3, 2015

With a fast-moving epidemic like Ebola, doctors need to make use of every tool at their disposal. This includes giving a second life to already-approved drugs....

One research team is hoping to ease the epidemic by shortening the lengthy drug development process.

Their approach? Sifting through hundreds of existing drugs and other compounds for ones that might work against the Ebola virus....

Additional screening narrowed the list down to two potential drug candidates: Bepridil, a calcium channel blocker used to treat heart disease, and sertraline, an antidepressant more commonly known as Zoloft.

Both drugs are already approved by the FDA, although not for use against the Ebola virus.

Read complete story.

http://www.healthline.com/health-news/zoloft-could-be-a-treatment-for-ebola-virus-060315#1

MEDICAL NEWS TODAY                                                    June 2, 2015
(Scroll down for study.)
Last year, in the 3 days before the outbreak was officially announced, over 60 million people received tweets about the Ebola outbreak in West Africa, say the authors of a new study published in the American Journal of Infection Control that investigates the useful role that Twitter can play in outbreak monitoring and control.

In the 3 days prior to Nigeria's official announcement about Ebola, Twitter users had already shared around 1,500 tweets about the outbreak....

Social media allow users to play active roles in spreading news. Users can share insights, opinions, fears and ideas, outside the contexts of conventional public health channels.

For their study, two researchers from Columbia University School of Nursing in New York, analyzed Ebola-related tweets posted over a week in the early stages of the West African outbreak - from July 24th to August 1st 2014....

BUSINESS STANDARD                                                                        April 27, 2015

HYDERABAD, India --Ella Foundation, which has taken up research for finding a potential vaccine for the deadly Ebola virus, today said it had successfully completed preliminary studies on the virus, which was responsible for high fatalities among humans in central Africa.

The Hyderabad-based foundation said it had completed the preliminary animal (with mice) experiments of the virus' glycoprotein with the targeted adenovirus, and the "immune response results have been good", which would be followed by toxicology tests and the subsequent clinical trials involving human beings.

Adenoviruses are responsible for respiratory infections, gastroenteritis, cystitis, and primary pneumonia in humans, and are therefore used as a clear target to understand the human immunity characteristics in laboratory. However, the efficacy of the vaccine is judged by the outcomes seen in human trials.

Read complete story.

http://www.business-standard.com/article/current-affairs/ella-foundation-announces-key-outcomes-in-ebola-vaccine-research-115042700631_1.html

REUTERS by Aharon Begley                                                                    Aug. 22, 2015
NEW YORK --An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak.

Although other experimental treatments appeared to help Ebola patients last year, especially in the United States, those one-time uses cannot prove efficacy against the "Makona" strain, since patients' recovery might be due to other causes. Similarly, drugs, including Mapp Biopharmaceutical's ZMapp, cured monkeys in lab experiments, but in a strain of Ebola different from that responsible for the current outbreak, the worst ever recorded.

"We can't say for certain that an experimental drug that works against one strain will work in another, even if they're almost identical genetically," said Thomas Geisbert of the University of Texas Medical Branch, senior author of the study published in the journal Nature.